[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"latent-tuberculosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:latent-tuberculosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,77,102,128,152,179,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100149071","training-protocol-on-the-natural-history-of-tuberculosis-100149071",false,"NCT01212003","Training Protocol on the Natural History of Tuberculosis","Natural History of Tuberculosis","* INCLUSION CRITERIA:\n\nFOR ALL PATIENTS\n\nPatients may be included in this study who:\n\n* Have or are suspected to have TB infection.\n* Are aged 2 years or older.\n* Have a primary care physician, infectious diseases physician, pulmonologist, or TB specialist outside of the NIH who can provide care of his or her TB infection outside the NIH, provide directly observed therapy (DOT) if necessary, and monitor for side effects and toxicity of TB medications.\n* Are willing to consent to storage of specimens for future research.\n* Able to provide informed consent for themselves or, if they lack the capacity to provide informed consent, have an appropriate Legally Authorized Representative (LAR; the study team will comply with NIH Human Research Protection Program \\[HRPP\\] Policy 403).\n\nFOR PATIENTS WITH LATENT TB\n\nIn addition to the above-described inclusion criteria for all patients, patients may be included in the Latent TB part of this protocol who:\n\n-Have documented evidence of a positive purified protein derivative (PPD) skin test or Interferon-gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)\u002FCDC guidelines for latent TB; conversion can have occurred at any time.\n\nFOR PATIENTS WITH ACTIVE TB\n\nIn addition to the above-described inclusion criteria for all patients, patients may be included in the Active TB part of this protocol who:\n\n* Have active TB of any drug susceptibility pattern and any site of infection as determined by smear, culture, or biopsy.\n* Have appropriately documented clinically suspicious active TB without definitive microbiology confirmation.\n\nEXCLUSION CRITERIA:\n\nPatients will be excluded from this study who:\n\n* Are incarcerated.\n* Have been ordered by a court to take TB medications.\n* Are unwilling or unable to comply with prescribed therapy.\n* Are pregnant.\n\nEXCLUSION OF SPECIFIC POPULATIONS\n\nChildren: Children under the age of 2 are not eligible to enroll. The addition of the very young will not provide enough additional insights to justify the risk to this specific population.\n\nPregnant women: Pregnant women are not eligible for participation in this protocol because the study objectives can be achieved without the enrollment of this population. Enrolled participants who become pregnant during the study will be withdrawn.","ALL","2 Years","100 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are interested in actively recruiting individuals with TB for research and treatment studies.\n\nObjectives:\n\n\\- To collect blood and other samples to study the natural history of tuberculosis.\n\nEligibility:\n\n\\- Individuals 2 years of age and older who have either active or latent tuberculosis.\n\nDesign:\n\n* Latent TB patients: Participants will have a single study visit with a physical examination and medical history, and will provide blood samples for testing.\n* Active TB patients: Participants will have an initial visit with a physical examination and medical history, and will provide blood samples for testing. Participants will also provide sputum samples if required, and may have an optional skin punch biopsy to collect a sample of skin tissue for study.\n* Treatment for active TB will be provided as part of this protocol.\n* Active TB participants may be asked to return for study visits every 1-2 months while receiving treatment....",[25,26,27,28,29],"Mycobacterium Infections","Tuberculosis, Multidrug-Resistant","Latent Tuberculosis","Tuberculosis","Extensively Drug-Resistant Tuberculosis",[31,32,33,27,34,35,28],"TB","Mycobacterium Tuberculosis","Active Tuberculosis","MDR TB","Natural History","RECRUITING","2026-06-17",{"date":39,"type":40},"2026-06-18","ACTUAL",{"date":42,"type":40},"2011-06-30",{"name":44,"class":45},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100322140","phase-2-assessment-of-the-safety-tolerability-and-effectiveness-of-rifapentine-given-daily-for-ltbi-100322140","NCT03474029","Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI","Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness","ASTERoiD","Inclusion Criteria\n\n1. Persons with LTBI who do not have evidence of TB disease (see exclusion criteria) and are at increased risk of progression to TB. LTBI or M. tuberculosis infection may be demonstrated by either a positive tuberculin skin test (TST) or a positive interferon gamma release assay (IGRA; e.g., QuantiFERON or T.SPOT.TB). Details of testing definitions and requirements for each risk factor are further described in the MOOP. Persons with LTBI at increased risk of progression to TB are those with at least one of the following:\n\n   1. Household and other close contacts (\\> 4 hours of exposure in a one-week period) within 2 years prior to enrollment, of persons with bacteriologically confirmed TB.\n\n      o Acceptable testing approaches for bacteriologic confirmation are 1) culture with rifamycin DST; or, 2) nucleic acid amplification tests (NAATs) that detect M. tuberculosis and detect mutations associated with rifamycin resistance. Additional details on bacteriologic confirmation, including accepted NAATs, will be included in the MOOP.\n   2. Recent M. tuberculosis infection, defined as converting from a documented negative to positive TST or IGRA within 2 years prior to enrollment. Persons without known close contact to someone with active pulmonary TB who have a conversion by IGRA may require additional evaluation to rule out a false conversion. Additional guidance and definitions of conversion are in the MOOP.\n   3. HIV co-infection (with CD4+ T-lymphocyte count \\> 100 cells\u002Fmm3)\n   4. ≥ 2 cm2 of pulmonary parenchymal fibrosis on chest X-ray and no prior history of treatment for TB or LTBI.\n   5. Recent (within 3 years prior to enrollment) immigration to the United States or other country with low to moderate TB incidence, with abnormal chest X-ray, and no evidence of active TB.\n   6. Recent (within 3 years prior to enrollment) immigration to the United States or other country with low to moderate TB incidence, from a country with an estimated incidence rate of TB \\> 150 per 100,000 (see Appendix D) and either a positive IGRA or a TST ≥15 mm (TST \\> 15 mm only applicable for those with recent immigration as their only risk factor for progression to TB).\n   7. Recent (within 3 years prior to enrollment) immigration and seeking refugee\u002Fasylum status (see MOOP for additional details) to the United States or other country with low to moderate incidence from a country with an estimated incidence rate of TB \\> 75 per 100,000 (see Appendix E) and either a positive IGRA or a TST ≥15 mm (TST \\> 15 mm only applicable for those with recent immigration as their only risk factor for progression to TB).\n   8. Individuals with an increased risk of TB due to medical conditions such as end-stage renal disease.\n   9. Individuals currently using immunosuppressive medications such as chronic steroids.\n   10. Individuals with planned use of TNF-α inhibitors.\n   11. Individuals with planned solid organ or hematologic transplantation\n2. Willing to provide signed informed consent, or parental permission and participant assent.\n3. For the following special populations, both inclusion criteria above must be met AND the criteria below depending on stage:\n\n   1. Pregnant women in their second or third trimester (≥14 weeks gestation).\n\n      * Stage 1: Include only those who agree to participate in the semi-intensive PK component.\n      * Stage 2: Include regardless of semi-intensive PK component participation.\n   2. Children aged less than 12 years\n\n      * Stage 1: Include only those who agree to participate in the semi-intensive PK component, based on enrollment strategy presented in Appendix I.\n      * Stage 2: Include regardless of semi-intensive PK component participation, based on PK findings and enrollment strategy described in Appendix I.\n\nExclusion Criteria\n\n1. Failure to document positive IGRA or TST\n2. Current breastfeeding.\n3. Women who are currently pregnant in their first trimester (\\\u003C14 weeks gestation) or intend to become pregnant within 120 days of enrollment.\n4. Non-pregnant women of childbearing potential who refuse to practice an adequate method of contraception (barrier method or non-hormonal intrauterine device) or abstain from activities that could lead to pregnancy.\n5. Current culture-positive TB, clinical TB, or suspected current TB. (Includes cases in which active TB cannot be excluded with reasonable clinical certainty by the site investigator. If sputum samples have been collected AND site investigators have suspicion of active TB, site investigators must wait to review culture results prior to enrollment.)\n6. TB resistant to any rifamycin in the source case\n7. A history of treatment for \\> 7 consecutive days (if daily dosing) with a rifamycin or \\>1 week (if weekly dosing) with a rifamycin and INH or \\> 30 consecutive days with INH within 2 years prior to enrollment.\n8. A documented history of completing an adequate course of treatment for TB disease or LTBI in a person who is HIV-seronegative.\n9. History of allergy or intolerance to rifamycins.\n10. Serum alanine aminotransferase (ALT; SGPT) or serum aspartate aminotransferase (AST; SGOT) \\> 5x upper limit of normal among persons in whom screening ALT or AST is determined.\n11. Receiving concomitant medications that are known to be contraindicated with any study drug.\n12. Weight \\\u003C 25 kg for participants ≥ 12 years, and weight \\\u003C 3kg for participants \\\u003C 12 years",{"count":56,"type":21},3400,"INTERVENTIONAL",[59,60],"PHASE2","PHASE3","This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care, control arm) of latent M. tuberculosis infection (LTBI).\n\nThis trial is conducted among persons who are at increased risk of progression to tuberculosis (TB) and require treatment of LTBI. The study will be conducted in low, medium and high TB incidence settings that have treatment of LTBI as their standard of care and offer 12-16 week rifamycin-based therapy as standard of care.\n\nThe hypothesis of this study is that the safety and effectiveness of the experimental treatment (6wP arm) is non-inferior to a comparator arm of 12-16 weeks of rifamycin-based treatment of LTBI (control arm).\n\nParticipants are enrolled and randomly assigned to one of the two study arms: experimental 6wP or control. The comparator (control) arm's treatment regimens include 12 weeks of once-weekly isoniazid (INH) and rifapentine (3HP), 12 weeks of daily INH and rifampin (3HR), and 16 weeks of daily rifampin (4R). A total of 560 participants per arm (1,120 total) for the evaluation of safety and 1,700 participants per arm (3,400 total) for the evaluation of effectiveness will be enrolled, given treatment as per randomization assignment, and followed for 24 months from the date of enrollment.\n\nAfter completion of data collection, statistical analyses will be conducted to compare proportions of drug discontinuation due to adverse drug reaction (ADR) and proportions of newly diagnosed tuberculosis between 6wP and control arm.",[27],[64,65],"latent tuberculosis","rifapentine","2026-05-04",{"date":68,"type":40},"2026-05-06",{"date":70,"type":40},"2019-08-01",{"date":72,"type":21},"2029-12-31",{"name":74,"class":75},"Centers for Disease Control and Prevention","FED",21,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":57,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100441018","economic-incentives-and-vdot-for-latent-tuberculosis-infection-100441018","NCT05022862","Economic Incentives and vDOT for Latent Tuberculosis Infection","Economic Incentives and Video Directly Observed Therapy to Promote Adherence to Latent Tuberculosis Infection","Inclusion Criteria:\n\n* 18 years old or older,\n* diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians\n* reside in Baltimore metro area\n* speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board\n* prescribed 3 months Isoniazid\u002FRifapentine, prescribed 3 months Isoniazid\u002FRifampin, or 4 months Rifampin\n\nExclusion Criteria:\n\n* younger than 18 years old\n* diagnosed with active TB\n* prescribed an alternative treatment regimen for latent TB\n* pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated)\n* participant's spoken language does not have a translated long or short consent form","18 Years",{"count":86,"type":21},399,[88],"NA","The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.",[27],[92],"Video Directly Observed Therapy","2026-04-30",{"date":66,"type":40},{"date":96,"type":40},"2022-02-07",{"date":98,"type":21},"2027-12-01",{"name":100,"class":101},"Johns Hopkins University","OTHER",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":57,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100517792","phase-3-tb-youth---tb-systemic-management-using-one-month-ultra-short-tpt-regimen-for-school-contacts-100517792","NCT06022146","TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts","TB-YOUTH","Inclusion Criteria:\n\n1. Aged ≥13 years and body weight ≥ 30 kg;\n2. School-registered individuals including:\n\n   * Currently attending junior \u002F senior high school or university students;\n   * School staff members;\n3. Close contacts of active pulmonary TB index cases (confirmed or clinically diagnosed) within the school, defined by meeting both of the following:\n\n   * Teachers\u002Fstudents sharing the same classroom or dormitory with the index case;\n   * Exposure history: Prolonged sharing of enclosed space (\\>4 hours total within 1 week) with the index case;\n4. Confirmed LTBI status through screening;\n5. Voluntary participation with signed informed consent form (for adults ≥18 years);\n6. Parental \u002F guardian consent and co-signed informed consent form (for minors aged 13-17 years).\n\nExclusion Criteria:\n\n1. Current active TB disease (clinically or bacteriologically confirmed);\n2. Documented isoniazid\u002Frifampicin resistance in the corresponding M. tuberculosis strain from the index case;\n3. Self-reported use of rifamycins (e.g., rifampicin, rifapentine) or isoniazid for \\>14 consecutive days within the past 2 years;\n4. Prior completion of full-course of treatment for ATB or LTBI;\n5. Hypersensitivity or intolerance to rifamycins (rifapentine \u002F rifampicin) or isoniazid;\n6. HIV positive serostatus or AIDS patients;\n7. History of viral hepatitis (e.g., chronic hepatitis B, chronic hepatitis C) or liver cirrhosis;\n8. Liver dysfunction (TBil\\>2.5mg\u002FdL \\[43umol\u002FL\\] or ALT \u002F AST\\>2ULN) or renal dysfunction.\n9. Current receiving immunosuppressive therapy or biological agents.\n10. Hematologic disorders with either PLT\\\u003C50×109\u002FL or WBC\\\u003C3.0×109\u002FL.\n11. Other conditions deemed unsuitable for TPT by investigators.","13 Years",{"count":111,"type":21},3520,[60],"This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.",[28,27],[64,116,117],"TPT","active screening","2025-12-15",{"date":120,"type":40},"2025-12-22",{"date":122,"type":40},"2023-09-01",{"date":124,"type":21},"2026-09-01",{"name":126,"class":101},"Huashan Hospital",47,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":16,"minAge":84,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100556560","lung-innate-immunity-and-microbiome-after-tuberculosis-exposure-100556560","NCT06526689","Lung Innate Immunity and Microbiome After Tuberculosis Exposure","Investigating the Impact of the Pulmonary Innate Immune Response and Microbiome After Exposure to Mycobacterium Tuberculosis","LIMBO-TB","Inclusion Criteria:\n\n1. Adults aged 18-65 years\n2. Resident in or near London or Oxford for the duration of the study period\n3. Provide written informed consent\n4. Willing to allow the investigators to review the volunteer's review NHS care record, medical history, blood results and radiographs.\n5. Able and willing (in the investigator's opinion) to comply with all study requirements\n\n   Group A and B Specific Inclusion Criteria\n6. Have undergone screening for TB through NHS services (including IGRA testing +\u002F- CXR where indicated)\n7. Close contact with a sputum smear positive TB case within the last 12 weeks\n\nExclusion Criteria:\n\n1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment or during the trial follow up period.\n2. History of anaphylaxis or any allergy likely to be exacerbated by any essential study procedure\n3. History of currently poorly controlled of airways disease (including asthma), current cancer (except BCC of the skin or CIS of the cervix), bleeding disorder, or drug or alcohol abuse\n4. Any significant autoimmune conditions or immunodeficiency (including HIV)\n5. Previous diagnosis or treatment for TB disease or latent TB infection\n6. Clinical, radiological, or laboratory evidence of current active TB disease\n7. Previous receipt of any investigational TB vaccines or aerosolised BCG.\n8. Clinically Significant abnormalities in spirometry.\n9. Concurrent use of oral, inhaled or systemic steroid medication or use for more than 14 days within the last 6 months (steroids used as a cream or ointment are permissible), or the use of other immunosuppressive agents concurrently or for more than 14 days within the last 6 months\n10. Use of antibiotics in the past 4 weeks.\n11. Administration of immunoglobulins and\u002For any blood products within the three months preceding the planned study\n12. Administration of a live vaccine within the preceding 28 days prior to enrolment.\n13. Administration of any other non-live vaccine within the preceding 14 days prior to enrolment.\n14. Pregnancy or intention to become pregnant during study period\n15. Any other significant disease, disorder, or finding, which, in the opinion of the investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data\n\n    Group C Specific Exclusion Criteria\n16. History of close contact with case of TB, or previous contact tracing by TB services.",true,"65 Years",{"count":139,"type":21},50,"To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure",[28,27],"2025-01-17",{"date":144,"type":40},"2025-01-22",{"date":146,"type":40},"2024-08-15",{"date":148,"type":21},"2028-10-01",{"name":150,"class":101},"University of Oxford",3,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":57,"phases":162,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":46},"100537746","phase-1-dolutegravir-pharmacokinetics-during-weekly-rifapentineisoniazid-for-tb-prevention-100537746","NCT06281834","Dolutegravir Pharmacokinetics During Weekly Rifapentine\u002FIsoniazid for TB Prevention","Inclusion Criteria:\n\n* (1) ART-naïve or ART-experienced HIV-infected children 4 weeks to \\\u003C12 years of age;\n* (2) no evidence of active TB based on an appropriate clinical evaluation;\n* (3) negative TB diagnostic test if performed (other than tuberculin skin testing);\n* (4) weight of at least 4 kilograms; and\n* (5) consent of the parent or legal guardian and assent of the child (if ≥7 years of age).\n\nExclusion Criteria:\n\n* (1) Baseline labs with evidence of ≥grade 3 abnormalities: alanine aminotransferase (ALT), total bilirubin, absolute neutrophil count (ANC), platelets, creatinine;\n* (2) presenting with acute respiratory distress or decompensation, or any clinical syndrome which could suggest undiagnosed TB or other opportunistic infection; or\n* (3) receipt of a medication that has drug-drug interactions with DTG or RPT.","4 Weeks","11 Years",{"count":161,"type":21},25,[163],"PHASE1","Tuberculosis (TB) is the leading cause of death among children living with HIV, yet insufficient data are available on the pharmacokinetics of newer TB prevention strategies in children. Short-course TB prevention\u002Flatent TB infection (LTBI) treatment regimens increase completion rates but have not been adequately studied among children living with HIV. Our prospective, open-label PK study will examine and extend use of weekly rifapentine and isoniazid (3HP) among children receiving dolutegravir. This will address gaps in knowledge by examining two-way PK of short-course LTBI treatment in a vulnerable pediatric population.",[166,27],"Pediatric HIV Infection",[168,65,169],"Pediatric HIV","TB prevention","2024-12-19",{"date":172,"type":40},"2024-12-24",{"date":174,"type":40},"2024-11-15",{"date":176,"type":21},"2027-06",{"name":178,"class":101},"Brigham and Women's Hospital",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":189,"studyType":22,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":46},"100444937","rifampicin-resistance-in-s-aureus-during-and-after-treatment-for-latent-tuberculosis-100444937","NCT05073926","Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis","Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis","Inclusion Criteria:\n\n* diagnosed with latent tuberculosis\n* prescribed either 4 months rifampicin or 6-9 months isoniazide\n* informed consent\n\nExclusion Criteria:\n\n* none","16 Years",{"count":188,"type":21},100,"10 Months","Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.",[27,192],"Staphylococcus Aureus",[194,195,196,64,197],"rifampicin","isoniazide","staphylococcus aureus","Drug Resistance, Microbial","2024-07-12",{"date":200,"type":40},"2024-07-15",{"date":202,"type":40},"2021-09-30",{"date":204,"type":21},"2026-12",{"name":206,"class":101},"Region Skane",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":136,"sex":16,"minAge":84,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":46},"100497387","prevalence-of-latent-tuberculosis-infection-in-health-care-workers-and-students-100497387","NCT05756582","Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students","Cross-sectional Study on Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students. A GENERATOR Infrastructure.","CROSSWORD","Inclusion Criteria:\n\n* all health-care workers of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome,\n* all students of all three-year and single-cycle degree courses, master's degree courses, graduate schools of the faculty of Medicine and Surgery of the Catholic University of Sacred Heart in Rome, trained at the Fondazione Policlinico Universitario A. Gemelli IRCCS,\n* written informed consent.\n\nExclusion Criteria:\n\n* denied informed consent.","72 Years",{"count":217,"type":21},2040,"This study is a cross-sectional study that examines the prevalence of Latent Tuberculosis Infection \\[LTBI\\], defined as individuals infected with Mycobacterium tuberculosis with no clinical evidence of disease, and the possible risk factors of LTBI in a large cohort of health care workers (HCWs) and students.",[28,220,221,27,222],"Tuberculosis, Pulmonary","Tuberculosis Infection","Health Care Associated Infection",[224,225,226,227],"latent tuberculosis infection","health-care workers","students","survey","2024-02-12",{"date":230,"type":40},"2024-02-13",{"date":232,"type":40},"2021-11-17",{"date":234,"type":21},"2026-12-15",{"name":236,"class":101},"Eleonora Nucera"]